Abstract

The immunomodulatory drugs (IMiDs), of which thalidomide was the first in class, have had a complex therapeutic history. Although these drugs are now widely used to treat multiple myeloma, the precise molecular mechanism of action of these agents has remained elusive. The finding that IMiDs bind cereblon, with subsequent activation of E3-ubiquitin ligase activity and degradation of the key transcription factors IKZF1 and IKZF3, has provided insight into these drugs but leaves many questions unanswered.

Original languageEnglish (US)
Pages (from-to)538-541
Number of pages4
JournalClinical Pharmacology and Therapeutics
Volume96
Issue number5
DOIs
StatePublished - Sep 17 2014

Fingerprint

Pharmaceutical Preparations
Thalidomide
Ubiquitin-Protein Ligases
Multiple Myeloma
Transcription Factors
History
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

The evolving tale of immunomodulatory drugs and cereblon. / Holstein, S. A.

In: Clinical Pharmacology and Therapeutics, Vol. 96, No. 5, 17.09.2014, p. 538-541.

Research output: Contribution to journalArticle

@article{fa5ca24b1a4a4d1fbf5783e2a956599a,
title = "The evolving tale of immunomodulatory drugs and cereblon",
abstract = "The immunomodulatory drugs (IMiDs), of which thalidomide was the first in class, have had a complex therapeutic history. Although these drugs are now widely used to treat multiple myeloma, the precise molecular mechanism of action of these agents has remained elusive. The finding that IMiDs bind cereblon, with subsequent activation of E3-ubiquitin ligase activity and degradation of the key transcription factors IKZF1 and IKZF3, has provided insight into these drugs but leaves many questions unanswered.",
author = "Holstein, {S. A.}",
year = "2014",
month = "9",
day = "17",
doi = "10.1038/clpt.2014.168",
language = "English (US)",
volume = "96",
pages = "538--541",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - The evolving tale of immunomodulatory drugs and cereblon

AU - Holstein, S. A.

PY - 2014/9/17

Y1 - 2014/9/17

N2 - The immunomodulatory drugs (IMiDs), of which thalidomide was the first in class, have had a complex therapeutic history. Although these drugs are now widely used to treat multiple myeloma, the precise molecular mechanism of action of these agents has remained elusive. The finding that IMiDs bind cereblon, with subsequent activation of E3-ubiquitin ligase activity and degradation of the key transcription factors IKZF1 and IKZF3, has provided insight into these drugs but leaves many questions unanswered.

AB - The immunomodulatory drugs (IMiDs), of which thalidomide was the first in class, have had a complex therapeutic history. Although these drugs are now widely used to treat multiple myeloma, the precise molecular mechanism of action of these agents has remained elusive. The finding that IMiDs bind cereblon, with subsequent activation of E3-ubiquitin ligase activity and degradation of the key transcription factors IKZF1 and IKZF3, has provided insight into these drugs but leaves many questions unanswered.

UR - http://www.scopus.com/inward/record.url?scp=84908210840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908210840&partnerID=8YFLogxK

U2 - 10.1038/clpt.2014.168

DO - 10.1038/clpt.2014.168

M3 - Article

C2 - 25144833

AN - SCOPUS:84908210840

VL - 96

SP - 538

EP - 541

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -